Re: Farmas USA
Enviado el: lunes, 10 de septiembre de 2012 18:00
Para: '[email protected]'; '[email protected]'
Asunto: Questions
Dear Mr. Renz and Ms. Nugent,
I bought 50K shares at $2 per share last year. I have seen Synavive’s today results. Why don’t you help small investors releasing good news with other study? For example: Prednisporin recent patent(you have not announced anything on this matter)or any news about Ionic Channel.
In your last conference, “JPM HealthCare” you were very optimistic with your studies, are you still so optimistic?
I hope your answer as a company investor.
Thank you for your attention.
Yours sincerely,
---------------------------------------------------------------------------------------------
De: Gina Nugent [mailto:[email protected]]
Enviado el: lunes, 10 de septiembre de 2012 18:10
Para:
CC: Justin Renz
Asunto: RE: Questions
Thank you for your interest in Zalicus. While we too are disappointed with the Synavive Phase 2b trial results, we remain optimistic about our Ion channel programs, both Z160 which recently entered Phase 2 development and Z944 which is expected to enter phase 2 development in the first quarter of 2013. We will continue to keep our shareholders informed on development progress as information becomes available.
Gina Nugent
P.D.: las acciones no las tengo a ese precio, y tengo 40k. Pero a veces suelen hacer mucho más caso si les planteas una situación más jodida...